GDNF-mediated rescue of the nigrostriatal system depends on the degree of degeneration
Sign Up to like & getrecommendations! Published in 2018 at "Gene Therapy"
DOI: 10.1038/s41434-018-0049-0
Abstract: Glial cell-line derived neurotrophic factor (GDNF) is a promising therapeutic molecule to treat Parkinson’s disease. Despite an excellent profile in experimental settings, clinical trials testing GDNF have failed. One of the theories to explain these… read more here.
Keywords: gdnf expression; nigrostriatal system; degeneration; nigrostriatal degeneration ... See more keywords
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Sign Up to like & getrecommendations! Published in 2022 at "Translational Neurodegeneration"
DOI: 10.1186/s40035-022-00288-z
Abstract: Background Growing evidence suggests an association between Parkinson’s disease (PD) and diabetes mellitus (DM). At the cellular level, long-term elevated levels of glucose have been shown to lead to nigrostriatal degeneration in PD models. However,… read more here.
Keywords: hyperglycemia; degeneration; long term; nigrostriatal degeneration ... See more keywords
Assessment of Repetitive and Compulsive Behaviors Induced by Pramipexole in Rats: Effect of Alpha-Synuclein-Induced Nigrostriatal Degeneration
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10030542
Abstract: Treatment with dopamine agonists in Parkinson’s disease (PD) is associated with debilitating neuropsychiatric side-effects characterized by impulsive and compulsive behaviors. The vulnerability to develop such impairments is thought to involve interactions between individual vulnerability traits,… read more here.
Keywords: degeneration; compulsive behaviors; effect; nigrostriatal degeneration ... See more keywords